DRF-funded project aims to screen for neurobehavioural issues

The Duchenne Research Fund is pleased to share an update on the Parent Project Muscular Dystrophy (PPMD) project we funded in the United States to address neurobehavioural and psychosocial issues in Duchenne. In 2021 we awarded an £80,000 grant to PPMD to support its...
Five-year grant to Dr Michela Guglieri: outcome report

Five-year grant to Dr Michela Guglieri: outcome report

We are delighted to report the outcomes of our grant for a Clinical Trials Lectureship. The grant, which was supported by a consortium of seven UK charities, saw the Duchenne Research Fund joined by Action Duchenne, Alex’s Wish, Duchenne Now, Duchenne UK, Harrison’s...

DMD Care UK: Psychosocial Programme now recruiting

The Duchenne Research Fund are pleased to announce that the University of Newcastle is now recruiting for a clinical psychologist to work with Duchenne patients and their families as part of the DMD Care UK Psychosocial Programme. This clinical and research-based role...

Santhera and ReveraGen share latest vamorolone study results

We are pleased to share the announcement from Santhera Pharmaceuticals and ReveraGen BioPharma of new topline results after completion of the VISION-DMD study at week 48. VISION-DMD was a pivotal double-blind Phase 2b study designed to demonstrate efficacy and safety...

DRF awards £640,000 for vital psychosocial project

The Duchenne Research Fund is delighted to announce that we are awarding a £640,000 grant to fund vital psychosocial care and research as part of Duchenne UK’s DMD Care UK programme. We are so pleased to partner with Duchenne UK on this important project. The...

DRF funds Duchenne clinic at Great Ormond Street

We are pleased to share that we have awarded a grant of £35,000 to Great Ormond Street Hospital to establish a dedicated clinic for children who are non-ambulant (no longer able to walk). The grant supports the post of Senior Physiotherapist Nicola Burnett (pictured)...

Solid announces collaboration with Ultragenyx

Ultragenyx Pharmaceutical and Solid Biosciences have announced a strategic collaboration and license agreement to focus on the development and commercialisation of new gene therapies for Duchenne. The collaboration brings together Solid’s expertise in muscle biology...

Two-year Vamorolone study completed

Santhera Pharmaceuticals has announced that partner ReveraGen Biopharma has completed a long-term, open-label extension study of 24 months duration with Vamorolone in patients with Duchenne muscular dystrophy. Including 6 months treatment in the preceding study,...

DRF-funded Imperial College AI study extended

The Duchenne Research Fund is pleased to share that the KineDMD study has been extended into 2021/22. KineDMD is Dr Aldo Faisal’s ground-breaking artificial intelligence study at Imperial College London, in collaboration with Great Ormond Street Hospital, which...

Martyn and Jessica trek Snowdonia to raise funds for DRF

Congratulations to Jessica and Martyn Jacobs who raised more than £3,300 through their Snowdonia trek to make a difference for all boys with Duchenne. We are so grateful for your support and look forward to putting the funds to great use. Click here to see our...